

<b>NCT ID</b>	NCT03935893
<b>Title</b>	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-05-02
<b>Location</b>	Pennsylvania, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03069469
<b>Title</b>	Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2017-03-03
<b>Location</b>	California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	DCC-3014
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04793958
<b>Title</b>	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2021-03-11

Location	Alabama, United States
	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Florida, United States
	Georgia, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Louisiana, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Nebraska, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	North Carolina, United States
	Ohio, United States
	Oklahoma, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Argentina
	Australia
	Austria
	Belgium
	Brazil
	Canada
	China
	Colombia
	Czechia
	Denmark
	Finland
	France
	Germany
	Greece
	Hong Kong
	Ireland
	Italy
	Korea, Republic of
	Malaysia
	Mexico
	Netherlands
	Poland
	Portugal
	Puerto Rico
	Romania
	Singapore
	Spain
	Taiwan
	Thailand
	Ukraine
	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes

<b>Status</b>	Active, not recruiting
<b>Drugs</b>	cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT01697371
<b>Title</b>	Proton Therapy in the Treatment of Liver Metastases
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2012-10-02
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03650348
<b>Title</b>	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-08-28
<b>Location</b>	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	PRS-343 in Combination with Atezolizumab, Tecentriq
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02537418
<b>Title</b>	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-09-01
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	durvalumab, Tremelimumab, Imfinzi
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02600949
<b>Title</b>	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-09
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Enrolling by invitation
<b>Drugs</b>	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

<b>NCT ID</b>	NCT04110093
<b>Title</b>	Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
<b>Phase</b>	Phase 1/Phase 2
<b>Date Added</b>	2019-10-01
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Regorafenib and PD-1 inhibitor
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT03668431
<b>Title</b>	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2018-09-12
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT03673787
<b>Title</b>	A Trial of Ipatasertib in Combination With Atezolizumab
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-09-17
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Ipatasertib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp